Advances in COVID-19 mRNA vaccine development
E Fang, X Liu, M Li, Z Zhang, L Song, B Zhu… - Signal transduction and …, 2022 - nature.com
To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …
SARS-CoV-2: evolution and emergence of new viral variants
VR Flores-Vega, JV Monroy-Molina… - Viruses, 2022 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent
responsible for the coronavirus disease 2019 (COVID-19). The high rate of mutation of this …
responsible for the coronavirus disease 2019 (COVID-19). The high rate of mutation of this …
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants in Qatar
Abstract SARS-CoV-2 Omicron BA. 1 and BA. 2 subvariants are genetically divergent. We
conducted a matched, test-negative, case-control study to estimate duration of protection of …
conducted a matched, test-negative, case-control study to estimate duration of protection of …
Effect of mRNA vaccine boosters against SARS-CoV-2 Omicron infection in Qatar
LJ Abu-Raddad, H Chemaitelly… - … England Journal of …, 2022 - Mass Medical Soc
Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
the emergence of the omicron (or B. 1.1. 529) variant of the severe acute respiratory …
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
Effects of previous infection and vaccination on symptomatic omicron infections
Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with …
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with …
The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus
Y Liu, J Rocklöv - Journal of travel medicine, 2021 - academic.oup.com
The Delta variant is now replacing all other SARS-CoV-2 variants. We found a mean R 0 of
5.08, which is much higher than the R 0 of the ancestral strain of 2.79. Rapidly ramping up …
5.08, which is much higher than the R 0 of the ancestral strain of 2.79. Rapidly ramping up …
mRNA-1273 COVID-19 vaccine effectiveness against the B. 1.1. 7 and B. 1.351 variants and severe COVID-19 disease in Qatar
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273
(Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic …
(Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic …
[PDF][PDF] COVID-19 weekly epidemiological update, edition 43, 8 June 2021
World Health Organization - 2021 - apps.who.int
Global case and death incidences continued to decrease with over 3 million new weekly
cases and over 73 000 new deaths, a 15% and an 8% decrease respectively, compared to …
cases and over 73 000 new deaths, a 15% and an 8% decrease respectively, compared to …
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study
Background Long-term effectiveness of COVID-19 mRNA boosters in populations with
different previous infection histories and clinical vulnerability profiles is inadequately …
different previous infection histories and clinical vulnerability profiles is inadequately …